Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis

Tanew, Adrian; Radakovic-Fijan, Sonja; Schemper, M.; Hönigsmann, Herbert

doi:10.1001/archderm.135.5.519

Cited by 133 publications

(138 citation statements)

References 28 publications

(27 reference statements)

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…UV photo-photochemotherapy are effective and well-established treatment modalities for psoriasis (3)(4)(5)(6)(7)(8). This study highlights that the clearing of psoriasis can be achieved faster by using PUVA than by using UVB-NB even though PUVA exposes the patient to a higher UV dose (p=O.OOl).…”

Section: Discussionmentioning

confidence: 80%

See 1 more Smart Citation

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

Brazzelli

Barbagallo

Trevisan

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

PUVA and UVB-NB phototherapy have an established role in the treatment of moderate-to-severe psoriasis. Even though psoriasis patients often require continuous treatments, inadequate attention is devoted to the duration of remission after the treatment. The purpose of this retrospective study is to assess which phototherapeutic regimen induces a longer remission. Twenty patients with psoriasis were included: 10 patients received PUVA and 10 patients received UVB-NB. We consider as a "cycle" the therapeutic period needed to reach clinical remission. The comparison between the average number of days in remission revealed that PUVA induces a longer remission period than UVB-NB: PUVA 386 days (ds ±321), UVB-NB 298 days (ds ± 257). Although the difference of the duration of remission is not statistically significant, a trend is seen and patients treated with PUVA remain clear for a period about 88 days longer than that of patients treated with UVB-NB. The differences in the duration of remission of psoriasis therapies must be considered in planning a patient's course of treatment.Psoriasis is a chronic inflammatory skin disease that affects about 0.5-4.6% of the general population (1). A variety of therapeutic options to treat psoriasis is available. The choice of treatment depends on the type, spread and severity of psoriasis, on the patient's age, the quality oflife and the consideration of treatment-associated long-term side risks (2).Photochemotherapy (Psoralen plus UVA, 365 nm) (PUVA) and DVB narrow-band (311 nm) phototherapy (UVB-NB) are well established and very efficient treatments for moderate-to-severe psoriasis (3-9).In literature, many trials evaluate the efficacy and adverse effects of therapies, but inadequate attention is devoted to the duration of remission (10), although it is one of the elements that most affects psoriatic patients' quality of life (11)(12). For this reason, the aim of our study is to assess which phototherapeutic regimen induces a longer remission. MATERIALS AND METHODSTwenty patients with moderate-to-severe psoriasis, resistant to topical treatments, were included in the study. The choice between PUVA or UVB-NB therapy was dictated only by the clinical and/or pharmacologic contraindications connected to PUVA therapy, and it had nothing to do with the different clinical forms, the extension or the gravity of psoriasis itself. Ten patients

show abstract

Section: Discussionmentioning

confidence: 80%

“…Photochemotherapy (Psoralen plus UVA, 365 nm) (PUVA) and DVB narrow-band (311 nm) phototherapy (UVB-NB) are well established and very efficient treatments for moderate-to-severe psoriasis (3)(4)(5)(6)(7)(8)(9).…”

mentioning

confidence: 99%

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

Brazzelli

Barbagallo

Trevisan

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…It can be used to treat skin diseases like vitiligo [19] and psoriasis [20]. The most important benefit of UV radiation is the formation of vitamin D. The "sunshine vitamin" has many positive effects on our health [21].…”

Section: Related Workmentioning

confidence: 99%

Personalized UV Radiation Risk Monitoring Using Wearable Devices and Fuzzy Modeling

2018

View full text Add to dashboard Cite

This paper presents a solution for monitoring of solar ultraviolet (UV) exposure and alerting about risks in real time. The novel system provides smart personalized indications for solar radiation protection. The system consists of a sensing device and a mobile application. The sensing device monitors solar radiation in real time and transmits the values wirelessly to a smart device, in which the mobile application is installed. Then, the mobile application processes the values from the sensory apparatus, based on a fuzzy expert system (FES) created from personal information (hair and eye color, tanning and burning frequency), which are entered by the user answering a short questionnaire. The FES provides an estimation of the recommended time of safe exposure in direct sunlight. The proposed system is designed to be portable (a wearable sensing device and smartphone) and low cost, while supporting multiple users.

show abstract

“…It appears to be useful for the treatment of age-related macular generation and choroidal melanoma (42). BPD-PDT also has been tested for treatment of atherosclerotic plaques (43) and psoriasis (44,45 (48), and mono-L-aspartyl chlorin e6 (NPe6; l abs @ 664 nm) has recently entered clinical trials for superficial malignancies of the skin and nasopharynx (49).…”

Section: Photosensitizers and Clinical Trialsmentioning

confidence: 99%

[No Title Available]

Sibata

Colussi

Oleinick

et al. 2000

Braz J Med Biol Res

155

View full text Add to dashboard Cite

A new concept in the therapy of both neoplastic and non-neoplastic diseases is discussed in this article. Photodynamic therapy (PDT) involves light activation, in the presence of molecular oxygen, of certain dyes that are taken up by the target tissue. These dyes are termed photosensitizers. The mechanism of interaction of the photosensitizers and light is discussed, along with the effects produced in the target tissue. The present status of clinical PDT is discussed along with the newer photosensitizers being used and their clinical roles. Despite the promising results from earlier clinical trials of PDT, considerable additional work is needed to bring this new modality of treatment into modern clinical practice. Improvements in the area of light source delivery, light dosimetry and the computation of models of treatment are necessary to standardize treatments and ensure proper treatment delivery. Finally, quality assurance issues in the treatment process should be introduced.

show abstract

Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis

Cited by 133 publications

References 28 publications

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

Personalized UV Radiation Risk Monitoring Using Wearable Devices and Fuzzy Modeling

[No Title Available]

Contact Info

Product

Resources

About